KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Common Equity (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Common Equity for 17 consecutive years, with $6.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 7.58% year-over-year to $6.1 billion, compared with a TTM value of $6.1 billion through Dec 2025, up 7.58%, and an annual FY2025 reading of $6.1 billion, up 7.58% over the prior year.
  • Common Equity was $6.1 billion for Q4 2025 at Biomarin Pharmaceutical, up from $6.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $6.1 billion in Q4 2025 and bottomed at $4.2 billion in Q1 2021.
  • Average Common Equity over 5 years is $5.0 billion, with a median of $4.8 billion recorded in 2023.
  • Peak annual rise in Common Equity hit 30.89% in 2021, while the deepest fall reached 4.02% in 2021.
  • Year by year, Common Equity stood at $4.3 billion in 2021, then grew by 7.91% to $4.6 billion in 2022, then grew by 7.57% to $5.0 billion in 2023, then increased by 14.27% to $5.7 billion in 2024, then grew by 7.58% to $6.1 billion in 2025.
  • Business Quant data shows Common Equity for BMRN at $6.1 billion in Q4 2025, $6.1 billion in Q3 2025, and $6.0 billion in Q2 2025.